author-photo

John C. Araujo

University of Texas MD Anderson Cancer Center

106

Papers

3337

Citations

Citation Trend

Filter By

Papers (77) Sort By

Journal Conference Others

Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience.

2021 International Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Outcomes in men with metastatic castrate-resistant prostate cancer treated with early platinum-based chemotherapy following an unsatisfactory response to androgen receptor (AR) inhibition as part of the phase II dynamic allocation modular sequential (DynAMo) trial.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer.

2021 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel

2021 medRxiv
Show All
- Source
- Cite
- Save
Citations (0)
The MD Anderson prostate cancer patient-derived xenograft series (MDA PCa PDX) captures the molecular landscape of prostate cancer and facilitates marker-driven therapy development.

2020 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (17)
Linking the Aggressive Variant Prostate Cancer (AVPC) molecular signature (-ms) to androgen indifference in a prospective clinical trial.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A phase II trial of Abiraterone followed by randomization to addition of Dasatinib or Sunitinib in men with metastatic castration resistant prostate cancer.

2020 Clinical Genitourinary Cancer
Show All
- Source
- Cite
- Save
Citations (3)
Clinical Outcomes in Men of Diverse Ethnic Backgrounds with Metastatic Castration Resistant Prostate Cancer.

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (7)
441 Outcomes of patients with metastatic renal cell carcinoma with intermediate- or poor-risk symptomatic disease who received their first cycle of nivolumab and ipilimumab while being hospitalized

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
636P A study of sustained androgen signaling dependence in metastatic castrate resistant prostate cancer (mCRPC)

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)